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ToxicitiesBackground and purpose: Sarcopenia is emerging as an adverse prognostic factor for survival and compli-
cation risk in cancer patients. This study aims to determine the impact of sarcopenia on survival and late
toxicity in a large cohort of head and neck squamous cell carcinoma (HNSCC) patients treated with defini-
tive (chemo)radiotherapy ((C)RT).
Materials and methods: HNSCC patients treated with definitive (C)RT from January 2007 to June 2016
were included. Sarcopenia was assessed from radiation planning computed tomography (CT) scans using
skeletal muscles at level C3. The impact of sarcopenia on overall survival (OS) and disease-free survival
(DFS) was evaluated using the Kaplan–Meier method. Multivariable association models were developed
to assess the impact of sarcopenia on late toxicity.
Results: The study population was composed of 750 HNSCC patients. Cut-off values for sarcopenia were
set at SMI < 42.4 cm2/m2 (men) and <30.6 cm2/m2 (women) corresponding lowest gender specific quar-
tile. Sarcopenic patients had significantly poorer survival rates, especially those with lower performance
status and locally advanced disease. In oropharyngeal cancer patients, survival was more determined by
p16 status than by sarcopenia. In multivariable analysis, sarcopenia was associated with worse OS (HR
0.72, p = 0.012) and DFS (HR 0.67, p = 0.001). In multivariable association models, sarcopenia was
associated with physician-rated xerostomia six months after treatment (OR 1.65, p = 0.027) and
physician-rated dysphagia six and twelve months after treatment (OR 2.02, p = 0.012 and 2.51,
p = 0.003, respectively).
Conclusion: Sarcopenia in HNSCC patients receiving definitive (C)RT is an independent prognostic factor
for worse survival outcomes and is associated with physician-rated toxicity.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology xxx (2020) xxx–xxx This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Prognosis for head and neck cancer (HNC) patients is deter-
mined by patient- and disease-related factors, such as age, weight
loss, performance status, comorbidities, prior malignancies, clinical
stage, and human papilloma virus (HPV) status [1–4]. Sarcopenia is
emerging as an independent adverse prognostic factor in all onco-
logical patients [5,6], as well as in HNC patients [7–16].
Sarcopenia is defined as severe loss of muscle mass and muscle
function [17]. It is associated with adverse outcomes in oncological
patients, including poorer survival, more postoperative infections,
increased length of hospital stay, and more chemotherapy-
induced dose limiting toxicity [5,6]. Poor alimentation, an impor-tant risk factor for developing sarcopenia, is very common in
patients with HNC. Approximately 35% to 60% of HNC patients pre-
sent with malnutrition and over 10% weight loss [18]. In addition,
HNC patients experience weight loss, gastrointestinal distress,
anorexia, fatigue, and sarcopenia before, during, and after their
oncological treatment [19]. Radiotherapy (RT) plays a pivotal role
in most HNC patients and is associated with many toxicities, like
xerostomia, dysphagia, oral mucositis, and sticky saliva, resulting
in further deterioration of nutritional status [19–22]. Combining
RT with systemic treatment modalities such as chemotherapy fur-
ther enhances these toxicities [23].
Recent studies, consisting of 85–246 HNC patients, confirmed
that sarcopenia is associated with poor overall survival (OS),
disease-free survival (DFS), chemotherapy toxicity, radiation treat-
ment breaks and post-operative wound complications after total
104 Sarcopenia and radiotherapy in head and neck cancerlaryngectomy [7–16]. No association between radiation-induced
toxicity and sarcopenia has been found yet [9].
Therefore, the purpose of this study was to investigate the asso-
ciation between sarcopenia and OS and DFS in a large cohort of
HNC patients treated with definitive RT and to investigate the rela-
tionship between sarcopenia and late radiation-induced toxicity.Materials and methods
Patient demographics and treatment
This single centre study used prospectively collected data which
was retrospectively analysed. A total of 750 consecutive head and
neck squamous cell carcinoma (HNSCC) patients were included,
treated between January 2007 and June 2016 at the University
Medical Center Groningen (UMCG). Patients were treated with
definitive RT, either combined or not, with systemic treatment (cis-
platin, carboplatin/5FU or cetuximab).
Inclusion criteria were as follows: confirmed primary tumour
with pathological diagnosis of squamous cell carcinoma, no meta-
static disease, treatment with curative intent, OS and DFS data
available, and participation in the prospective data registry pro-
gram for HNC patients, as described in previous studies [24,25].
In summary, this program includes a prospective evaluation of tox-
icity and quality of life prior to, weekly during, and at regular inter-
vals after definitive or postoperative RT or chemoradiotherapy
(CRT) (at 6 weeks, every 6 months up to 24 months, and every
12 months up to 60 months).
Details about the RT regimens used are described in detail in
previous studies [26,27]. In summary, RT consisted of three-
dimensional conformal radiotherapy (3D-CRT), intensity-
modulated radiation therapy (IMRT) or volumetric arc therapy
(VMAT) using a simultaneous integrated boost (SIB) technique to
a total prescribed dose of 70 Gy with fractions of 2 Gy in 6–7 weeks
(6 or 5 fractions per week). Most patients received bilateral neck
radiation with a prophylactic dose of 54.25 Gy. Patients with
locally advanced disease below 70 years of age who were deemed
fit enough received concurrent chemotherapy, or cetuximab if
chemotherapy was contraindicated. Chemotherapy consisted of
carboplatin 300–350 mg/m2 on day 1, 22 and 43 followed by con-
tinuous infusion of 5-fluorouracil at a dose of 600 mg/m2/day for
96 h. Cetuximab was started one week before radiotherapy at a
loading dose of 400 mg/m2, followed by weekly infusions of
250 mg/m2 during radiotherapy.Clinical parameters
All clinical parameters, including age, gender, height, weight,
World Health Organization Performance Status (WHO PS), smoking
history, alcohol history, p16 status, tumour location and treatment
modality were derived from the prospective data registration.
Mean dose of the primary tumour, positive lymph nodes and
organs at risk (OARs) was derived from the RT planning system.
Tumour (T) and lymph node (N) stage were defined according to
the 7th edition of the American joint Committee on Cancer Staging
Manual [28].Fig. 1. A transversal CT-slice at the level of C3. Purple: right sternocleidomastoid
muscle; green: paravertebral muscle; red: left sternocleidomastoid muscle. (For
interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)CT image analysis
Sarcopenia can be assessed on CT scans. Measurement of a sin-
gle abdominal image can provide estimates of total body skeletal
muscle mass and adipose tissue distribution [29]. In oncological
patients, sarcopenia is determined based on single-slide CT mea-
surement of the cross-sectional muscle area (CSA) at the level of
the third lumbar vertebra (L3) [30]. Swartz et al. [31] found astrong correlation between skeletal muscle mass at level L3 and
skeletal muscle mass at the level of the third cervical vertebra (C3).
For all patients, sarcopenia was assessed on the pre-treatment
CT scan (Somatom Sensation Open, Siemens, Forchheim, Germany;
voxel size 1.0  1.0  2.0 mm; scan voltage: 120 kV; convolution
kernel: B30) with contrast enhancement acquired for RT treatment
planning, according to the method previously published by Swartz
et al. [31]. This method was validated by Ufuk et al. [32].
The single axial CT-slide at level of C3 first showing the entire
vertebral arc when scrolling from caudal to cranial direction was
selected. To avoid over- or underestimation of skeletal muscle area,
the Hounsfield unit (HU) settings ranged from 29 to +150 HU
[31,33]. Outer contours of both sternocleidomastoid and paraver-
tebral muscles were delineated manually (Fig. 1) using the delin-
eation software Mirada DBx 1.2.0. All CT-scans were delineated
by a single researcher (MvR) and supervised by an experienced
head and neck radiation oncologist (RS).
The cross sectional muscle area (CSA) at the level of C3 is the
total volume of the delineated areas divided by the thickness of
the CT-slide. The CSA (cm2) of the skeletal muscle at C3 was used
to estimate the CSA at L3 using the validated algorithm described
by Swartz et al. (Eq. (1)) and was furthermore adjusted for patients
height (m2) resulting in skeletal muscle index (SMI, cm2/m2) (Eq.
(2)) [31,32].
CSA at L3 cm2
  ¼ 27:304þ 1:363  CSA at C3 cm2  0:671
 age yearsð Þ þ 0:640 weight kgð Þ
þ 26:442
 sex sex ¼ 1 for female;2 for maleð Þ ð1Þ









Cut-off values for sarcopenia were set at SMI according lowest
gender specific quartile.Table 1a
Baseline characteristics of the patients.
Characteristic No sarcopenia Sarcopenia P value
(n = 555) (%) (n = 189) (%)
Gender 0.697b
Male 412 (74.2) 143 (75.7)
Female 143 (25.8) 46 (24.3)
Age at diagnosis 62 ± 10 66 ± 10 <0.001cOutcome measures
Outcome measures included OS, DFS and late radiation-induced
toxicity. The time-to-event was defined from the first day of RT to
the date of death or the date of disease recurrence. Patients alive or
without any event were censored at the date of last follow up. For
late radiation-induced toxicity endpoints were patient-rated and
physician-rated xerostomia and physician-rated dysphagia, six
and twelve months after treatment. Patient-rated xerostomia was
defined as moderate-to-severe patient-rated xerostomia using
the European Organisation for Research and Treatment of Cancer
EORTC QLQ-H&N35 questionnaires [34]. Physician-rated xerosto-
mia and dysphagia were both defined as grade 2  toxicity using
the Common Terminology Criteria for Adverse Events (CTCAE,
v4.03) [35].(median ± SD) (years)
WHO PS <0.001b
0 390 (70.3) 94 (49.7)
1–3 165 (29.7) 95 (50.3)
SMI at diagnosis 45.7 ± 7.2 36.7 ± 5.3 <0.001c
(median ± SD) (cm2/m2)
Smoking history 0.002b
Never 53 (9.5) 13 (6.9)
Yes, current smoker 256 (46.1) 118 (62.4)
Yes, in the past 244 (44.0) 58 (30.7)
Missing 2 (0.4) 0 (0.0)
Alcohol history 0.022b
Never 117 (21.1) 24 (12.7)
Yes, current drinker 381 (68.8) 135 (71.4)
Yes, in the past 53 (9.6) 29 (15.3)
Missing 3 (0.5) 1 (0.5)
Tumour site <0.001b
Hypopharynx 38 (6.8) 33 (17.5)
Larynx 273 (49.2) 58 (30.7)
Oral cavity 27 (4.9) 16 (8.5)
Oropharynx 189 (34.1) 80 (42.3)
Nasopharynx 28 (5.0) 2 (1.1)
P16 status (oropharynx tumours) 0.001b
Positive 83 (43.9) 16 (20.0)
Negative 91 (48.1) 57 (71.3)
Missing 15 (8.0) 7 (8.7)
T stagea <0.001b
Tis 3 (0.5) 1 (0.5)
T1 105 (18.9) 17 (9.0)
T2 180 (32.4) 54 (28.6)
T3 142 (25.6) 39 (20.6)
T4 125 (22.5) 78 (41.3)
N stagea 0.002b
N0 267 (48.1) 62 (32.8)
N1 48 (8.6) 16 (8.5)
N2 223 (40.2) 106 (56.1)
N3 17 (3.1) 5 (2.6)
Clinical stagea <0.001b
Stage I 71 (12.8) 13 (6.9)
Stage II 114 (20.5) 32 (16.9)
Stage III 110 (19.8) 22 (11.6)
Stage IV 260 (46.8) 122 (64.6)
Treatment modality 0.072b
RT only 338 (60.1) 101 (53.4)
RT with systemic treatment 217 (39.1) 88 (46.6)
RT technique 0.534b
Conventional 65 (11.7) 19 (10.1)
IMRT 490 (88.3) 170 (89.9)
Abbreviations: SMI = skeletal muscle index; WHO PS = World Health
Organization performance score; T = tumour, N = lymph node;
RT = radiotherapy; IMRT = intensity modulated radiotherapy.
a According to the 7th edition of the AJCC/UICC staging system.
b P value was calculated using the chi-square test.
c P value was calculated using the independent samples t-test.Data analysis
Descriptive statistics were calculated, the continuous variables
were presented as mean (standard deviation, SD) or median (in-
terquartile range, IQR) and discrete variables were presented as
frequency counts and percentages. The T-test and Chi-square test
were used to calculate differences between groups.
Kaplan–Meier estimates of survival proportions over time were
calculated for patients with or without sarcopenia using log-rank
tests or Wilcoxon tests in case of crossing survival curves. Stratified
survival analysis was performed by WHO PS, i.e. WHO PS 0 versus
WHO PS 1–3, by stage of disease, i.e. stage I–II versus stage III–IV
and by p16 status in patients with oropharynx tumours, i.e. p16-
negative vs. p16-positive. The risk factors for time to death and dis-
ease progression or recurrence were analysed using Cox propor-
tional hazards models. Univariable models were fit to determine
the hazard associated with sarcopenia, age, gender, WHO PS, smok-
ing history, alcohol history, p16 status, tumour stage, tumour loca-
tion, treatment modality, and RT technique. Covariates for the
multivariable Cox proportional hazards regression models were
selected using stepwise-forward selection with the condition p-
value = 0.157.
Association models, using multivariable logistic regression,
were developed to analyse the association of sarcopenia with the
toxicity endpoints [36]. Association models are used to estimate
the relationship between an outcome variable and a determinant
while correcting for confounding. Potential confounders, i.e. age,
gender, body mass index (BMI), WHO PS, smoking history, tumour
stage, tumour location, treatment modality, RT technique, and
mean dose on OARs, were evaluated with Pearson’s Chi-Squared
test or Spearman’s Rank Correlation coefficient. Variables with
p < 0.10 were selected and added to the analysis as potential con-
founders. Confounders resulting in more than 10% change of the
regression coefficient were considered relevant confounders for
the effect of sarcopenia on the endpoints.
Statistical analyses were performed using IBM Statistical Pack-
age for Social Sciences (SPSS) version 23. Data from all included
patients were used and missing values were not imputed in
analysis.
Results
The median follow up for the entire cohort was 24 months (IQR
12–56) and 315 deaths (42.0%) were observed. SMI was calculatedin 744 patients, since information on patient height was missing in
six patients. Mean SMI of the total population was 43.4 (SD 7.8)
cm2/m2, significantly higher in men than in women (resp. 46.3
and 34.9 cm2/m2, p < 0.001). Sarcopenia cut-off values correspond-
ing with the lowest gender specific quartile were set at SMI < 42.
4 cm2/m2 in men and <30.6 cm2/m2 in women.
Patients with sarcopenia were more likely to be older (66 vs.
62 years, p < 0.001), or to have a worse WHO PS, i.e. WHO PS
1–3 (50.3% vs. 29.7%, p < 0.001). They were less likely to have a
tumour located in the larynx (30.7% vs. 49.2%, p < 0.001), to have
stage I or II disease (23.8% vs. 33.3%, p < 0.001), or to have
106 Sarcopenia and radiotherapy in head and neck cancerp16-positive oropharyngeal cancer (20.0% vs. 43.9%, p = 0.001)
(Table 1a).
Three-year OS and DFS in sarcopenic patients were 56% and 48%
versus 75% and 69% in non-sarcopenic patients, respectively (both
p < 0.001). The effect of sarcopenia was most pronounced in the
first two years after treatment (Fig. 2).
In patients with WHO PS 0, or early stage disease, (stage I–II),
sarcopenia was not significantly associated with OS (p = 0.154
and p = 0.532 resp.), whereas in patients with worse performance
(WHO PS 1–3), or locally advanced disease (stage III-IV), sarcopenic
patients had a significantly worse OS Estimated three-year OS in
sarcopenic patients with worse performance and sarcopenic
patients with locally advanced disease were 37% and 48%
(p < 0.001) versus 59% and 70% (p < 0.001) in non-sarcopenic
patients, respectively. No significant association between sarcope-
nia and OS was found in patients with an oropharynx tumour after
stratification by p16 status, i.e. p16-negative (p = 0.561 and
p = 0.118, resp. log-rank test and Wilcoxon test) versus p16-
positive (p = 0.150) (Fig. 3). Results regarding DFS were similar.
Sarcopenia was a independent predictor for worse OS and DFS.
After adjustment for confounders including age, WHO PS, smoking
history, p16 status, primary tumour site, tumour stage, and treat-
ment modality, multivariable Cox proportional hazards models
showed that for patients without sarcopenia the HR for OS was
0.72 (95% CI 0.56–0.93, p = 0.012) and 0.67 (95% CI 0.53–0.86,
p = 0.001) for DFS (Table 2).
Sarcopenic patients were more likely to experience moderate-
to-severe patient-rated xerostomia (15.9% vs. 8.1%, p < 0.001) and
grade 2  physician-rated dysphagia (33.9% vs. 20.0%, p = 0.001)
at baseline (Table 1b). The percentages of sarcopenic and non-
sarcopenic patients with radiation-induced toxicities six and
twelve months after treatment, are shown in Fig. 4. Patients with
sarcopenia seemed to have grade 2  physician-rated xerostomia
and grade 2  physician-rated dysphagia more often, both six
and twelve months after treatment. In multivariable analysis, after
correction for confounders, such as toxicity at baseline, i.e. the pre-Fig. 2. Kaplan-Meier curves of overall survival, p < 0existing experienced toxicity at start of treatment, and mean dose
at OARs, a significant association was found between sarcopenia
and physician-rated xerostomia six months after treatment (OR
1.65 (95% CI 1.06–2.57), p = 0.027) and physician-rated dysphagia
both six and twelve months after treatment (OR 2.02 (95% CI 1.17–
3.51), p = 0.012 and OR 2.51 (95% CI 1.36–4.65), p = 0.003, resp.)
(Supplements, Tables 1–3). However, for patient-rated xerostomia
no significant association was found with sarcopenia.Discussion
This large cohort study of 750 HNSCC patients confirmed that
sarcopenia is an independent adverse prognostic factor for OS
and DFS, especially in patients with worse performance, (WHO
PS 1–3), or locally advanced disease, (stage III–IV). In addition, this
study shows that sarcopenia is associated with radiation-induced
physician-rated xerostomia at six months and dysphagia six and
twelve months after treatment.
Our study confirmed that sarcopenia in HNC patients treated
with definitive (C)RT is strongly associated with worse OS and
DFS (7,9,10,13,14). Additionally, we were the first to investigate
the impact of sarcopenia on survival outcomes when stratified
for WHO PS or disease stage and found that sarcopenia is strongly
associated with worse outcomes in patients with worse perfor-
mance. This finding is supported by a recent study from Zwart
et al. in which sarcopenia was associated with frailty in HNC
patients with locally advanced disease [37]. A hypothesis is that
skeletal muscle depletion is a marker of more advanced disease.
However, no studies confirmed this, partly because most studies
only included patients with locally advanced disease.
Our study showed that sarcopenia was not a significant factor
with regard to OS in HNSCC patients with oropharyngeal carci-
noma when stratified for p16 status. This finding is in contrast to
a smaller study consisting of 113 patients with advanced oropha-
ryngeal cancer, which showed that sarcopenia was a prognostic
factor affecting OS independent of HPV status [10]. However, after.001 (A) and disease-free survival, p < 0.001 (B).
Fig. 3. Kaplan-Meier curves of overall survival stratified by WHO PS (WHO PS 0, p = 0.154 (A) and WHO PS 1–3, p < 0.001 (B)), stage of disease (stage I–II, p = 0.532 (C) and
stage III–IV, p < 0.001 (D)), and p16 status in patients with an oropharynx tumour (p16 negative, p = 0.541 (E) and p16 positive, p = 0.150 (F)). Abbreviation: WHO PS = World
Health Organization performance status.
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Table 1b
Baseline toxicities of the patients.
Baseline toxicity No sarcopenia Sarcopenia P value
(n = 555) (%) (n = 189) (%)
Patient-rated xerostomia <0.001a
None – a bit 458 (82.5) 127 (67.2)
Moderate-to-severe 45 (8.1) 30 (15.9)
Missing 52 (9.4) 32 (16.9)
Physician-rated xerostomia 0.437a
Grade 0 478 (86.1) 154 (81.5)
Grade 1 71 (12.8) 30 (15.9)
Grade 2 1 (0.2) 0 (0.0)
Missing 5 (0.9) 5 (2.6)
Physician-rated dysphagia 0.001a
Grade 0–1 434 (78.2) 121 (64.0)
Grade 2 76 (13.7) 38 (20.1)
Grade 3 22 (4.0) 17 (9.0)
Grade 4–5 13 (2.3) 9 (4.8)
Missing 10 (1.8) 4 (2.1)
a P value was calculated using the chi-square test.
108 Sarcopenia and radiotherapy in head and neck cancerinclusion of p16 status in the multivariable Cox proportional haz-
ards model of all our HNSCC patients sarcopenia remained an inde-
pendent significant adverse prognostic factor for OS and DFS.
Apart from worse survival outcomes, we also found that sar-
copenia is significantly associated with grade 2  physician-rated
xerostomia six months after treatment, and grade 2  physician-
rated dysphagia at both six and twelve months after treatment,
after correction for baseline toxicity and other confounders. How-
ever, no significant association was found between sarcopenia and
patient-rated xerostomia six and twelve months after treatment,
and physician-rated xerostomia 12 months after treatment, after
correction for confounders. A possible explanation for the signifi-
cant association between sarcopenia and physician-rated xerosto-
mia while association between sarcopenia and patient-rated
xerostomia is lacking, might be that grade 2  physician-rated
xerostomia is defined as a multi-item endpoint, consideringTable 2
Cox regression analysis of overall survival and disease-free survival.
Overall su
(n = 720)
Variable HR (95% C
Univariate analysis
Gender (male vs. female) 1.05 (0.81
Age 1.02 (1.01
WHO PS (0 vs. 1–3) 0.38 (0.31
Sarcopenia (no vs. yes) 0.52 (0.41
Smoking history (never vs. ever) 0.68 (0.42
Alcohol history (never vs. ever) 0.88 (0.66
P16 status (negative vs. positive) 1.81 (1.18
Tumour stage (I–II vs. III–IVb) 0.52 (0.39
Primary tumour site (larynx vs. other) 0.50 (0.39
Treatment modality (RT alone vs. RT with systemic treatment) 0.64 (0.51
Technique (conventional vs. IMRT) 0.68 (0.48
Multivariable analysis
Age 1.03 (1.01
WHO PS (0 vs. 1–3) 0.44 (0.35
Sarcopenia (no vs. yes) 0.72 (0.56
Smoking history (never vs. ever)
P16 status (negative vs. positive) 0.51 (0.33
Primary tumour site (larynx vs. other) 0.58 (0.43
Tumour stage (I–II vs. III–IVb)
Treatment modality (RT alone vs. 0.65 (0.48
RT with systemic treatment)
Abbreviations: HR = hazard ratio; CI = confidence interval; WHO PS = World Health O
radiotherapy.
*Wald test statistically significant.dietary changes next to xerostomia. Therefore, we hypothesize that
sarcopenia affects swallowing, and not salivary gland functioning.
To our knowledge, only Nishikawa et al. [9] have investigated
the correlation between sarcopenia and radiation-induced toxici-
ties in HNC patients. These investigators did not find an association
between sarcopenia and acute toxicities, including dermatitis,
mucositis and aspiration pneumonia, and late toxicities such as
xerostomia, dysgeusia and hypothyroidism, but this study only
included 39 patients which is perhaps not a large enough sample.
Other studies found a significant association between skeletal
muscle mass and increased acute grade  3 toxicities in patients
with oesophageal cancer treated with CRT [38] and in patients
with pancreatic cancer receiving stereotactic body RT [39]. Mur-
imwa et al. suggest that the increased radiation-induced acute tox-
icities in sarcopenic patients may be due to the pro-inflammatory
state of these patients [38].
This increased radiation-induced toxicity in sarcopenic patients,
negatively impacts their quality of life since Langendijk et al.
showed that xerostomia and dysphagia have a significant impact
on quality of life [40]. Moreover, a recent literature review showed
that sarcopenia itself was associated with an obvious decline in
quality of life [41]. Therefore, quality of life in this patient popula-
tion might be affected by both radiation-induced toxicities and
sarcopenia.
Despite intensive nutritional support, nutritional status gen-
erally deteriorates during RT [19,22]. Loss of skeletal muscle
mass during (C)RT cannot be prevented by tube-feeding [7,16].
In contrast, recent studies showed that intensive nutritional,
physical and psychological interventions minimize weight loss,
increase muscle mass and strength, improve treatment tolerance
and result in less fatigue and better quality of life [42–46].
Therefore, it might be interesting to investigate whether sar-
copenia is a potentially modifiable risk factor to improve patient
outcome.
The current study has some limitations. First, in this retrospec-
tive cohort analysis, the patients were divided into two groups,rvival Disease-free survival
(n = 720)
I) P value HR (95% CI) P value
–1.36) 0.712 1.13 (0.88–1.45) 0.342
–1.03) 0.002* 1.02 (1.00–1.03 0.007*
–0.48) <0.001* 0.43 (0.35–0.54) <0.001*
–0.66) <0.001* 0.51 (0.40–0.64) <0.001*
–1.08) 0.098 0.61 (0.39–0.96) 0.031*
–1.19) 0.413 0.89 (0.67–1.18) 0.426
–2.78) 0.006* 0.51 (0.34–0.76) 0.001*
–0.67) <0.001* 0.54 (0.42–0.69) <0.001*
–0.63) <0.001* 0.53 (0.42–0.66) <0.001*
–0.81) <0.001* 0.70 (0.57–0.87) 0.001*
–0.96) 0.030* 0.65 (0.46–0.91) 0.013*
–1.04) <0.001* 1.02 (1.01–1.03) 0.004*
–0.56) <0.001* 0.53 (0.42–0.67) <0.001*
–0.93) 0.012* 0.67 (0.53–0.86) 0.001*
0.62 (0.38–0.99) 0.044*
–0.80) 0.003* 0.47 (0.31–0.71) <0.001*
–0.78) <0.001* 0.53 (0.41–0.70) <0.001*
0.69 (0.51–0.94) 0.018*
–0.87) 0.004*
rganization performance status; RT = radiotherapy, IMRT = intensity modulated
Fig. 4. Percentage of patients without and with sarcopenia with late radiation-
induced toxicity. Abbreviations: M06 = six months after treatment; M12 = twelve
months after treatment.
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specific quartile. Therefore, the two study arms are not statistically
balanced. Instead, this study shows that sarcopenic patients had
other baseline characteristics than non-sarcopenic patients. Sec-
ond, CSA at L3 is estimated based on the CSA at C3, resulting in
some uncertainty, although two other recent studies showed the
L3-method used for delineation provides reproducible measure-
ments and is robust [47,48]. Jung et al. developed another predic-
tion model for estimating the CSA at L3 with the same variables as
Swartz et al. [31], but other coefficients [49]. Moreover, they
showed high predictability of skeletal muscle mass at C3 alone
for estimating OS after curative treatment for advanced stage
HNC [49], which might make the conversion to CSA at L3 unneces-
sary. However, this method has not yet been externally validated.
Third, no consensus regarding cut-off values for sarcopenia has
been reached in the literature, which makes it more difficult to
compare results. Our study, like some others, used a gender speci-
fic threshold corresponding to the lowest 25th percentile [50,51].
We considered using existing cut-off values of a comparable
patient cohort [8,52]. Wendrich et al. developed one optimal cut-
off value for low skeletal muscle mass as a predictor for
chemotherapy dose limiting toxicity, which was set at 43.2 cm/
m2 for both men and women [8]. The female patients in the current
cohort had significantly lower SMI-values than males. Therefore,
we decided to use a gender specific cut-off value. If cut-off values
of Prado et al. [52] would have been used in the current study pop-
ulation, the majority (i.e. 82%) of our patients would have been
classified as sarcopenic. In addition, the cut-off values of Prado
et al. [52] were based on an obese population (mean BMI
34.3 kg/m2), whereas the mean BMI in our population was
25.6 kg/m2.
In conclusion, sarcopenia is a common and relevant problem in
HNC patients and is associated with poor OS and DFS, especially in
patients with worse performance and locally advanced disease. In
contrast, sarcopenia is not a significant factor with regard to sur-
vival outcomes in oropharyngeal cancer patients. In addition, sar-
copenia might be associated with radiation induced toxicities.
Given that the SMI can be easily assessed on CT scans, clinical
introduction is easy and adds important and clinically relevant
information to assess patient outcome.Conflict of interest
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